COYA 300
Alternative Names: COYA-300Latest Information Update: 06 Dec 2022
At a glance
- Originator Coya Therapeutics
- Class Antidementias; Cytokines
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Frontotemporal dementia
Most Recent Events
- 06 Dec 2022 Discontinued - Preclinical for Frontotemporal dementia in USA (SC)
- 22 Sep 2022 Preclinical trials in Frontotemporal dementia in USA (SC) (Coya Therapeutics pipeline, September 2022)
- 22 Sep 2022 Coya Therapeutics intends to file IND application for phase I trial in Frontotemporal dementia in 1H of 2023 (Coya Therapeutics pipeline, September 2022)